Cardiovascular Intervention and Therapeutics

, Volume 32, Issue 4, pp 405–408 | Cite as

Does anticoagulation therapy prevent thrombosis in coronary stent grafts?

  • Yuki Honda
  • Kohei WakabayashiEmail author
  • Takayasu Suzuki
  • Hiroshi Suzuki
Case Report


A polytetrafluoroethylene (PTFE)-covered stent was deployed for enlarging coronary aneurysms in a 73-year-old man. Optical coherence tomography (OCT) and coronary angioscopy performed 3 months later revealed naked stent struts and thin patches of red thrombi covering the PTFE membrane even under dual antiplatelet therapy (DAPT). After 5-month warfarin administration under DAPT, OCT and angioscopy showed a clear extinction of the thin patches of red thrombi on the PTFE membrane and stent struts, although most of the struts were still naked. The addition of anticoagulation therapy to DAPT may reduce thrombosis events in patients treated with PTFE-covered stents.


Polytetrafluoroethylene (PTFE)-covered stent Stent thrombosis Anticoagulation therapy Angioscopy 


Compliance with ethical standards

Conflict of interest

None of the authors has any potential financial conflict of interest related to this manuscript.


The present study was approved by the ethics committee at each participating site and was conducted in accordance with the Declaration of Helsinki.

Supplementary material

Supplementary material 1 (AVI 189908 kb)

Supplementary material 2 (AVI 134107 kb)


  1. 1.
    Romaguera R, Waksman R. Covered stents for coronary perforation: is there enough evidence? Catheter Cardiovasc Interv. 2011;78:246–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Kawamoto H, Tanaka K, Ruparelia N, Takagi K, Yabushita H, Watanabe Y, et al. Short-term and long-term outcomes after polytetrafluoroethylene-covered stent implantation for the treatment of coronary perforation. Am J Cardiol. 2015;116:1822–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Takano M, Yamamoto M, Inami T, Murakami D, Seino Y, Mizuno K. Delayed healing of a coronary stent graft. J Am Coll Cardiol Cardiovasc Interv. 2011;4:466–7.CrossRefGoogle Scholar
  4. 4.
    Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal. J Am Coll Cardiol. 2005;45:456–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in angicoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2011;57:173–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–62.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Association of Cardiovascular Intervention and Therapeutics 2016

Authors and Affiliations

  • Yuki Honda
    • 1
  • Kohei Wakabayashi
    • 2
    Email author
  • Takayasu Suzuki
    • 3
  • Hiroshi Suzuki
    • 4
  1. 1.Division of CardiologyFuji HospitalShizuokaJapan
  2. 2.Division of Cardiology, Department of Internal MedicineShowa University Koto-Toyosu HospitalTokyoJapan
  3. 3.Division of Cardiovascular SurgeryFuji HospitalShizuokaJapan
  4. 4.Division of Cardiology, Department of Internal MedicineShowa University Fujigaoka HospitalYokohamaJapan

Personalised recommendations